Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 6/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937936 | 0.89 | PTGDR2 (0.43) | PTGDR2CCR5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL8038110 | 0.82 | ALDH1A1 (0.59) | PTGDR2KDM4EALDH1A1SMN1; SMN2SYK | |
| SCHEMBL15474708 | 0.81 | SYK (0.63) | KDM4EALDH1A1SMN1; SMN2SYKAURKB | |
| SCHEMBL29690396 | 0.80 | PTGDR2 (0.61) | PTGDR2CCR5ALDH1A1SMN1; SMN2PTPN1 | |
| SCHEMBL82269 | 0.80 | PTGDR2 (0.61) | PTGDR2CCR5ALDH1A1SMN1; SMN2PTPN1 | |
| SCHEMBL1406392 | 0.79 | ALDH1A1 (0.48) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL29989288 | 0.78 | SYK (0.57) | CCR5KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL29195674 | 0.78 | CCR5 (0.51) | CCR5KDM4EALDH1A1SYKAURKB | |
| SCHEMBL17385133 | 0.78 | SYK (0.57) | CCR5KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL15475096 | 0.78 | TUBB1 (0.61) | KDM4EALDH1A1SMN1; SMN2SYKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| EP-1831170-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | AstraZeneca AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006065204-A1 | SUBSTITUTED AMINOPYRIDINES AND USES THEREOF | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287399-A1 | Substituted Aminopyridines and Uses Thereof | PSEN2, SLC1A2, PSEN1 | PTGDR2 1159/4885CCR5 3283/4885KDM4E 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.